HOME >> MEDICINE >> NEWS
Drug Is First In Decade To Show Promise Treating Generalized Anxiety Disorder

BOSTON -- A drug commonly prescribed for depression has shown great promise in treating a serious, yet highly under-recognized condition called Generalized Anxiety Disorder (GAD), according to new study led by Duke psychiatrist Dr. Jonathan Davidson.

Davidson said the anti-depressant drug, venlafaxine extended release (XR), is the first new therapy in 10 years to be proven clearly effective in treating symptoms of GAD, a mental disorder characterized by persistent, excessive anxiety and worry over routine life activities. The condition can be serious enough to impair social and job functioning, and often includes physical symptoms such as fatigue, trembling, muscle tension, headache and nausea. Depression is found in 30 percent to 50 percent of GAD patients.

Findings of the study, funded by Wyeth-Ayerst Laboratories, will be presented in Boston March 26 at a scientific symposium held in conjunction with the 18th National Conference of the Anxiety Disorders Association of America.

"This condition is a very prevalent, yet frustrating medical condition to treat because physicians often fail to correctly diagnose it and have limited treatment options," Davidson said. "The new findings are important because they demonstrate the potential for expanded treatment options for this chronic disorder."

In the eight-week, multi-center study of 405 non-depressed patients with GAD, Davidson and colleagues compared the effects of venlafaxine XR to both a placebo (sugar pill) and to a commonly used anti-anxiety medication called buspirone.

Results showed that venlafaxine XR was superior to the placebo in its ability to reduce symptoms, especially feelings of worry, tension and being on edge. Both doses of venlafaxine XR -- 75 mg and 150 mg -- were more effective than the placebo. Nausea was the most commonly reported side effect. Buspirone, however, was not more effective than the placebo, although previous
'"/>

Contact: Rebecca A. Levine
Levin005@mc.duke.edu
919-684-4148
Duke University Medical Center
26-Mar-1998


Page: 1 2 3

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2020)... , ... September 01, 2020 , ... ... has completed $3 million convertible note financing, which will be used to accelerate ... the funds from this financing, the company will continue to expand its customer ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... Health Network (AHN), are joining biomedical engineers from Carnegie Mellon University (CMU) to ... for cardiac patients who have undergone open heart surgery. , The AGH/CMU team ...
(Date:8/31/2020)... ... 2020 , ... Want to get moving, break up your routine, and make ... thrilled to launch its fourth annual STEPtember campaign in the United States to raise ... wherever they are at this moment — encouraging people to move in the ways ...
(Date:8/31/2020)... ... August 31, 2020 , ... The pandemic and topsy-turvy economic outlook continues to put ... and look for ways to trim the fat from our monthly expenses and put more ... it’s also important that you have a financial safety net in place in case something ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... improve outcomes for patients with advanced heart failure, today announced that the company ... the amount of $555,358 from the National Heart, Lung, and Blood Institute of ...
Breaking Medicine News(10 mins):
(Date:9/1/2020)... ... ... Breast and ovarian cancers are common diseases that affect many women. ... 7,500 women per year) and 10% of ovarian cancers (about 2,000 women per year) ... detectable in the Women’s Excellence Genetic Testing Program. , Dr. Jonathan Zaidan, MD, FACOG, ...
(Date:8/31/2020)... ... August 31, 2020 , ... Cloudticity ... has named Cloudticity a Gold winner in the 15th Annual 2020 Network PG’s ... o ns from Network Products Guide honoring achievements of world’s best ...
(Date:8/27/2020)... ... 2020 , ... Austin Oral Surgery – an oral and maxillofacial surgery practice ... DDS, MD, has joined the practice. An accomplished oral and maxillofacial surgeon, Dr. Szalay’s ... scheduled to open this fall. The new office is slated for 1601 E. Pflugerville ...
Breaking Medicine Technology:
Cached News: